Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2013-07-16 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2013-07-16 English
PRIMARY DOCUMENT
Director's Dealing
2013-07-16 English
PRIMARY DOCUMENT
Director's Dealing
2013-07-16 English
PROSPECTUS SUPPLEMENT
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q Quarterly Report filed pursuant to the Securities Exchange Act of 1934 for the quarterly period ended April 30, 2013. It contains detailed unaudited condensed consolidated financial statements, management's discussion and analysis, notes to financial statements, and other required disclosures typical of a quarterly report. The document length is substantial (15,000 characters), and it includes actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2013-06-19 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares of common stock by CopyTele, Inc. It includes extensive information about the offering, selling stockholders, risk factors, use of proceeds, management discussion and analysis, executive compensation, and financial statements. The presence of detailed offering terms, selling stockholders, and registration details indicates this is a capital raising document. The document is not an earnings release, annual report, or management discussion alone, but a prospectus related to a securities offering and resale. Therefore, it fits the category of Capital/Financing Update (CAP).
2013-06-19 English
FORM 10-Q/A
Interim / Quarterly Report Q3 2013
2013-06-19 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.